文献速递临床试验与 GCP基础与转化研究

恢复期血浆治疗重型与危重型COVID-19的随机临床试验

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

该多中心开放标签随机试验纳入103例重型或危重型COVID-19患者,比较恢复期血浆联合标准治疗与单用标准治疗。28天内临床改善率两组差异无统计学意义,但恢复期血浆组72小时病毒PCR转阴率显著更高。试验因提前终止可能把握度不足。

核心结论

  • 在重型或危重型COVID-19患者中,恢复期血浆联合标准治疗相比单用标准治疗,未显著改善28天内临床改善时间。
  • 试验提前终止可能使研究把握度不足,无法检测出临床重要差异。

研究设计与样本

  • 开放标签、多中心随机临床试验,在中国武汉7个医疗中心进行,时间为2020年2月14日至4月1日,最终随访至2020年4月28日。
  • 纳入103例实验室确诊的COVID-19患者,病情为重型(呼吸窘迫和/或低氧血症)或危重型(休克、器官衰竭或需机械通气)。
  • 计划入组200例,实际入组103例后提前终止。
  • 干预为恢复期血浆联合标准治疗(n=52)对比单用标准治疗(n=51),按疾病严重程度分层。

主要发现

  • 28天死亡率:恢复期血浆组15.7% vs 对照组24.0%,OR 0.59(95%CI 0.22-1.59),P=0.30。

关键数值与推荐

  • 主要结局为28天内临床改善时间,定义为存活出院或6点疾病严重度量表(1分出院至6分死亡)下降2分。
  • 次要结局包括28天死亡率、出院时间及基线阳性至72小时内病毒PCR转阴率。
  • 恢复期血浆组2例患者在输血后数小时内出现不良事件,经支持治疗后好转。

临床怎么用

  • 恢复期血浆不宜作为重型或危重型COVID-19患者的常规标准治疗推荐。
  • 对重型患者可考虑恢复期血浆以促进病毒清除,但需结合临床综合判断。
  • 临床决策时应考虑该试验提前终止导致的统计把握度不足。

局限性

  • 试验提前终止,仅入组103例(计划200例),可能把握度不足。
  • 开放标签设计可能引入偏倚。
  • 样本量较小,亚组分析结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed. OBJECTIVE: To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Open-label, multicenter, randomized clinical trial performed in 7 medical centers in Wuhan, China, from February 14, 2020, to April 1, 2020, with final follow-up April 28, 2020. The trial included 103 participants with laboratory-confirmed COVID-19 that was severe (respiratory distress and/or hypoxemia) or life-threatening (shock, organ failure, or requiring mechanical ventilation). The trial was terminated early after 103 of a planned 200 patients were enrolled. INTERVENTION: Convalescent plasma in addition to standard treatment (n = 52) vs standard treatment alone (control) (n = 51), stratified by disease severity. MAIN OUTCOMES AND MEASURES: Primary outcome was time to clinical improvement within 28 days, defined as patient discharged alive or reduction of 2 points on a 6-point disease severity scale (ranging from 1 [discharge] to 6 [death]). Secondary outcomes included 28-day mortality, time to discharge, and the rate of viral polymerase chain reaction (PCR) results turned from positive at baseline to negative at up to 72 hours. RESULTS: Of 103 patients who were randomized (median age, 70 years; 60 [58.3%] male), 101 (98.1%) completed the trial. Clinical improvement occurred within 28 days in 51.9% (27/52) of the convalescent plasma group vs 43.1% (22/51) in the control group (difference, 8.8% [95% CI, -10.4% to 28.0%]; hazard ratio [HR], 1.40 [95% CI, 0.79-2.49]; P = .26). Among those with severe disease, the primary outcome occurred in 91.3% (21/23) of the convalescent plasma group vs 68.2% (15/22) of the control group (HR, 2.15 [95% CI, 1.07-4.32]; P = .03); among those with life-threatening disease the primary outcome occurred in 20.7% (6/29) of the convalescent plasma group vs 24.1% (7/29) of the control group (HR, 0.88 [95% CI, 0.30-2.63]; P = .83) (P for interaction = .17). There was no significant difference in 28-day mortality (15.7% vs 24.0%; OR, 0.59 [95% CI, 0.22-1.59]; P = .30) or time from randomization to discharge (51.0% vs 36.0% discharged by day 28; HR, 1.61 [95% CI, 0.88-2.95]; P = .12). Convalescent plasma treatment was associated with a negative conversion rate of viral PCR at 72 hours in 87.2% of the convalescent plasma group vs 37.5% of the control group (OR, 11.39 [95% CI, 3.91-33.18]; P < .001). Two patients in the convalescent plasma group experienced adverse events within hours after transfusion that improved with supportive care. CONCLUSION AND RELEVANCE: Among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days. Interpretation is limited by early termination of the trial, which may have been underpowered to detect a clinically important difference. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2000029757.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020. PMID: 32492084. doi:10.1001/jama.2020.10044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。